omacetaxine mepesuccinate   Click here for help

GtoPdb Ligand ID: 7454

Synonyms: CGX-635 | HHT | homoharringtonine | Myelostat® | Synribo®
Approved drug PDB Ligand
omacetaxine mepesuccinate is an approved drug (FDA (2012))
Compound class: Natural product
Comment: Omacetaxine mepesuccinate is a semi-synthetic derivative of the alkaloid cephalotaxine from Cephalotaxus harringtonia. Note that this compound is represented on Drugbank with slightly different stereochemistry by the entry DB04865.

omacetaxine mepesuccinate is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 123.99
Molecular weight 545.26
XLogP 1.72
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC(=O)CC(C(=O)OC1C(=CC23C1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O
Isomeric SMILES COC(=O)C[C@@](C(=O)O[C@@H]1C(=C[C@]23[C@@H]1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O
InChI InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
InChI Key HYFHYPWGAURHIV-JFIAXGOJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
This drug was designated as an orphan drug for rare diseases by the European Medicines Agency (EMA) in 2004, for treatment of chronic myeloid leukemia (CML). In 2012, the US FDA granted full approval for the same indication, in patients who have shown resistance and/or intolerance to two or more tyrosine kinase inhibitors.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Omacetaxine inhibits protein translation. It is hypothesised that the drug binds to the A site of the 60S ribosomal subunit, preventing entry of charged tRNAs, thereby preventing elongation of nascent proteins [2,4]. The cells undergo cell cycle arrest [5] and apoptose [1].
External links Click here for help
For extended ADME data see the following:

Drugs.com
European Medicines Agency (EMA)